extended its offer of $69 a share, or $18.5 billion, for
to Feb. 15.
The tender offer was previously scheduled to expire last Friday, Jan. 21. All terms and conditions of the tender offer remain unchanged, Sanofi said in a statement Monday.
Sanofi, the French drugs giant, said it and Genzyme are discussing the structure of a contingent value right involving Genzyme's Lemtrada, a multiple sclerosis drug, as part of any transaction. Sanofi said "significant differences" remain on the potential contingent value right.
Sanofi said as of Jan. 21, about 0.4% of Genzyme's shares has been tendered.
Shares of Genzyme, the U.S. biotechnology company, closed Friday at $71.58.
-- Written by Joseph Woelfel
>To contact the writer of this article, click here:
>To submit a news tip, send an email to: